Embed Size (px)
Citation preview
Charting the Biosimilar and Biobetter
Development PipelineCHARTVIEWS
September 2012
Charting the Biosimilar and Biobetter Development Pipeline
A FirstWord ChartViews Report
CHARTVIEWS
Charting the Biosimilar and Biobetter
Development Pipeline
All Contents Copyright © 2012 Doctor’s Guide Publishing Limited. All Rights Reserved
September 20122
www.fwreports.com
CHARTVIEWS
US and EU patent expiries of 20 leading originator products
Brand US Patent Expiry EU Patent Expiry Sales 2011 (USD $m)
Epogen, Procrit, Eprex 2013 <=20111 3,730
Avonex 2013 <=2011 2,687
Humalog 2013 <=2011 2,368
Eprex 2013 <=2011 1,623
Erbitux 2018 <=2011 1,820
Novolin <=2011 <=2011 1,916
Remicade 2012 2012 7,200
Herceptin 2019 2012 5,770
Rituxan 2015 2013 6,596
Lantus 2014 2014 5,190
Neulasta 2014 2015 3,950
Aranesp 2014 2015 2,997
Botox 2014 2016 1,775
Rebif 2015 2016 2,235
NovoLog 2017 2016 2,274
Humira 2016 2017 7,932
Avastin 2019 2018 6,596
Lucentis 2019 2018 3,723
Advate 2015 2019 2,210
Enbrel 2028 2021 7,870
1 <=2011: patent expiry before or on 2011
Charting the Biosimilar and Biobetter
Development Pipeline
All Contents Copyright © 2012 Doctor’s Guide Publishing Limited. All Rights Reserved
September 20123
www.fwreports.com
CHARTVIEWS
Top 20 reference biologics by global sales US$million 2011
Humira
9000
Glo
bal S
ales
, US$
m
8000
7000
6000
5000
4000
3000
2000
1000
0
Enbrel
Remicade
Avastin
Rituxa
n
Herceptin
Lantus
Neulasta
Epogen; Procri
t; Eprex
Lucentis
Aranesp
Avonex
Humalog
NovoLog
Rebif
Advate
Novolin
Erbitux
BotoxEprex
Charting the Biosimilar and Biobetter
Development Pipeline
All Contents Copyright © 2012 Doctor’s Guide Publishing Limited. All Rights Reserved
September 20124
www.fwreports.com
CHARTVIEWS
Number of biosimilars in development by therapy area
Haematology
90
100
110
Num
ber o
f bio
sim
ilars
in d
evel
opm
ent
80
70
60
50
40
30
20
10
0
Oncology
Endocrine and Metabolic Disorders
Infectious and Parasitic Disease
Musculoskeletal Disorders
Neurology
Obstetrics/gynaecology
Cardiovascular Diseases
Gastrointestinal D
isorder
Respiratory Disease
Autoimmune Disease
Ophthalmology
Neuromuscular Diseases
Charting the Biosimilar and Biobetter
Development Pipeline
All Contents Copyright © 2012 Doctor’s Guide Publishing Limited. All Rights Reserved
September 20125
www.fwreports.com
CHARTVIEWS
Number of biosimilars and biobetters being developed by companies by revenue
160
Number of biosimilars in revenue class
Number of biobetters in revenue class
140
120
100
80
60
40
20
<10US$million 10-100US$million 100-999US$million 1000-9999US$million 10,000US$million+0
Charting the Biosimilar and Biobetter
Development Pipeline
All Contents Copyright © 2012 Doctor’s Guide Publishing Limited. All Rights Reserved
September 20126
www.fwreports.com
CHARTVIEWS
Biobetters by class and earliest potential launch date in the EU
35302520151050
2018-2020
>=2021
2012-2014
<=2011
2015-2017
Immunomodulators
Interferons
mAb Immunomodulators
Cytotoxic mAbs
Erythropoietin
G-CFS
Insulin
Others (Enzymes, BCF)
Other Hormones
